Tue, January 10, 2023

Gil Blum Maintained (SRPT) at Strong Buy with Increased Target to $160 on, Jan 10th, 2023

Gil Blum of Needham, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Increased Target from $158 to $160 on, Jan 10th, 2023.

Gil has made no other calls on SRPT in the last 4 months.



There are 7 other peers that have a rating on SRPT. Out of the 7 peers that are also analyzing SRPT, 1 agrees with Gil's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $141 on, Thursday, October 13th, 2022


These are the ratings of the 6 analyists that currently disagree with Gil


  • Yun Zhong of "BTIG" Maintained at Strong Buy with Increased Target to $160 on, Thursday, December 22nd, 2022
  • Colin Bristow of "UBS" Upgraded from Hold to Strong Buy and Increased Target to $158 on, Friday, December 16th, 2022
  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy with Increased Target to $138 on, Tuesday, November 29th, 2022
  • Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $190 on, Thursday, November 3rd, 2022
  • Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $171 on, Thursday, November 3rd, 2022
  • Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $145 on, Monday, October 17th, 2022